Patricia Industries’ holding Atlas Antibodies acquires evitria, leader in recombinant antibody expression
Atlas Antibodies, a leading provider of highly validated research antibodies, has signed an agreement to acquire evitria. evitria is a quality leader within custom recombinant antibody expression serving the biopharmaceutical industry. The acquisition brings together two highly innovative companies, with double digit organic growth over the last five years, to create an antibody-focused platform, serving a wide range of customers, with combined LTM adjusted EBITDA of approximately SEK 130m. Patricia Industries will contribute its 70 percent of Atlas Antibodies, with a reported book value of